Forbes magazine named Bristol-Myers Squibb the “Best Pharmaceutical Company of 2013”

Corporate information

BMS

11/01/14

"Forbes" magazine conducted a comprehensive evaluation of 16 pharmaceutical companies with a market value of more than 50 billion US dollars based on indicators such as stock market performance, research and development results, medical progress, business ethics, business adjustments and strategic transformation (medical device companies are not included in the selection). Bristol-Myers Squibb ranked first in the overall ranking due to its excellent performance in the past year and its research and development achievements in the field of oncology.

"Forbes" believes that in 2013, Bristol-Myers Squibb insisted on taking the path of biopharmaceuticals; its immuno-oncology therapy was rated as "Major Breakthrough of the Year" by "Science" magazine; in the fiercely competitive field of hepatitis C treatment research and development, the company's performance is also remarkable. Moreover, in recent years, Bristol-Myers Squibb's strategy has always been clear and its performance has been stable.

Bristol-Myers Squibb began its transformation into a biopharmaceutical company in 2007 and has continued its biopharmaceutical strategy since then. By the end of 2013, Bristol-Myers Squibb had a market capitalization of $87 billion, with its stock price rising 61.4% over the past year.